Abstract
GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Current Drug Delivery
Title:Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Volume: 15 Issue: 5
Author(s): Rawda Y. AlSheyyab*, Bashar M. Al-Taani, Rana M. Obeidat, Motasem M. Alsmadi, Rafeef K. Masaedeh and Raghda N. Sabat
Affiliation:
- Jordan University of Science and Technology, Pharmaceutical Technology, Irbid, Jordan,Jordan
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Abstract: GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Export Options
About this article
Cite this article as:
AlSheyyab Y. Rawda *, Al-Taani M. Bashar , Obeidat M. Rana , Alsmadi M. Motasem , Masaedeh K. Rafeef and Sabat N. Raghda , Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists, Current Drug Delivery 2018; 15 (5) . https://dx.doi.org/10.2174/1567201815666180214142300
DOI https://dx.doi.org/10.2174/1567201815666180214142300 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets The Correlation between Lipid Metabolism Disorders and Prostate Cancer
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Anti-Cancer Agents in Medicinal Chemistry Mini-Review: Bmx Kinase Inhibitors for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Microarrays and Mass Spectrometry - The Future of Proteomics
Current Genomics Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Synthesis of Unsymmetrical C5-Curcuminoids as Potential Anticancer Agents
Letters in Drug Design & Discovery Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design